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Abstract
Objective: To measure the long-term impact of surgical treatment for vulval cancer upon health-
related quality of life and pelvic ﬂoor outcomes during the ﬁrst year of therapy.
Methods: Prospective, longitudinal, mixed-methods study. Twenty-three women aged >18 years
with a new diagnosis of vulval cancer were recruited. The EORTC QLQ C30, SF-36 and an electronic
pelvic ﬂoor assessment questionnaire (ePAQ-PF) were administered at baseline (pre-treatment) and 3,
6, 9 and 12 months post-treatment. Mixed effects repeated measures models (all adjusted for age and
BMI) were used to investigate changes over time and differences between cancer stage. Qualitative in-
terviews were carried out with 11 of the women and analysed using a thematic approach.
Results: Mean age was 59.9 years (SD= 15.3; range = 23.8–86.6 yrs). Mean BMI was 30.0 (SD= 4.5;
range = 24.4–38.2). Sixteen women had early (Stage 1 to 2B), and seven women had advanced stage
disease (Stage 3 to 4B). Questionnaire scores revealed that physical and social functioning, fatigue,
pain and general sex life were signiﬁcantly worse at 12 months than pre-treatment (p =< 0.05). Qual-
itative analysis revealed multiple treatment side effects which were perceived as severe and enduring.
Women with advanced vulval cancer had signiﬁcantly worse SF-36 mental health scores at 12 months
compared to women with early stage disease (p = 0.037).
Conclusions: Surgery for vulval cancer has long-term implications which can be persistent 12months
post-treatment. High rates of morbidity relating to lymphoedema and sexual function re-enforce the
need for specialist clinics to support women who suffer these complications.
© 2015 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
Introduction
In the UK, vulval cancer accounts for approximately 8%
of gynaecological cancers (Cancer Research UK, 2014)
[1]. However, numbers are increasing especially in youn-
ger women [2]. This is linked to increasing incidence of
vulval intraepithelial neoplasia (VIN) because of infection
with the human papilloma virus (HPV) [3,4].
Although some women will receive primary radiother-
apy, the main treatment is surgery to remove the tumour
including a one cm area of healthy tissue [5]. The treat-
ment pathway undertaken depends upon several factors.
Women with at least stage 1B disease are also offered
inguinofemoral lymphadenectomy, if co-morbidity per-
mits, to assess lymph node involvement. Adjuvant radio-
therapy and concomitant chemotherapy may be given if
adverse prognostic factors, e.g. close surgical margins or
spread to the inguinal lymph nodes are present.
However, despite advances in treatment, morbidity and
complications are still high with 40% of women experien
cing short-term complications such as wound breakdown
and infection and 28% developing long-term lymphoe
dema. Women who have short-term complications, after
groin node dissection, are more likely to develop long-
term complications [6–8].
A systematic review in 2006 identiﬁed no studies which
had assessed the impact of treatment upon the health-
related quality of life (HRQoL) of women with vulval can-
cer [9]. More recent reviews conclude that whilst there is
still a paucity of research, surgery for vulval cancer creates
numerous challenges and impacts upon many areas of
quality of life including sexual, psychological and
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relationship functioning [5,10]. Several qualitative re-
search papers also support these ﬁndings [6,11–15].
One key limitation of the quantitative data on the
HRQoL of women with vulva cancer is that most of the
data has been collected post-treatment, and therefore
the change in HRQoL as a consequence of treatment could
not be quantiﬁed [16–24]. Very little prospective, longitu-
dinal patient-reported outcome data is available that
includes a pre-treatment baseline assessment [25–27].
In response to the lack of prospective studies, our aim
was to use qualitative and quantitative methods to com-
prehensively investigate the long-term impact that surgery
for vulva cancer has upon patient outcomes and explore
how this may change during the ﬁrst 12 months from
diagnosis to post-treatment.
Methods
Women attending the Shefﬁeld Gynaecological Cancer
Centre between March 2007 and December 2009 with a
new diagnosis of vulval cancer were approached to partic-
ipate in the study by their clinician. Those interested were
given the patient information sheets by HW and asked to
return the consent form within one week if willing to par-
ticipate. We aimed to recruit as many women as possible
within this period. With a sample size of 20, 80% power
and 5% two-sided signiﬁcance, the minimum standardised
effect size we could detect is 0.66 (using n=23, this value
would be 0.61).
Ethical approval
Ethical Approval was obtained from the North Shefﬁeld
Ethics Committee (05/Q2308/153).
Data collection
Demographic data was recorded on a proforma. Clinical
data was completed immediately prior to treatment and
at subsequent visits. Questionnaires to measure HRQoL
and pelvic ﬂoor function were administered at baseline
(pre-treatment) and then at 3, 6, 9 and 12 months post-
treatment. It has been argued that because generic mea-
sures have been designed to measure HRQoL across a
wide variety of conditions, they may not be sensitive
enough to assess changes in speciﬁc illnesses and there-
fore a disease speciﬁc measure should also be used [28].
Therefore, the cancer-speciﬁc European Organisation for
Research on Treatment of Cancer (EORTC-QLQ-30)
[29] and the Short Form-36 (SF-36) were administered
[30]. Because of the nature of the surgery upon the vulva
and vagina, we also administered the electronic Personal
Assessment Questionnaire-Pelvic Floor (ePAQ-PF). It is
a web-based interactive questionnaire which provides an
in-depth evaluation of a woman’s pelvic ﬂoor symptoms
and their impact upon HRQoL [31,32].
Statistical analysis
The statistical package for the social sciences (SPSS) for
windows, Version 20 (IBM, Armonk, USA) was used.
All graphs were plotted using the statistical package R (R
Foundation for Statistical Computing, Vienna, Austria).
Questionnaires were scored according to their appropriate
scoring algorithms. Changes over time in the domain scores
and differences in follow-up domain scores between early
stage (stages 1 and 2 were combined as the cancer was con-
ﬁned to the vulva) and advanced stage cancer (included
stage 3 and stage 4) were investigated using mixed effects
repeated measures models. Using the approach suggested
by Walters [33], three difference models were ﬁtted: (a)
HRQoL Domain Score=Time+BMI+Age; (b) HRQoL
Outcome=Baseline Score+Time+Stage+Time×Stage
Interaction+BMI+Age; (c) HRQoL Outcome=Baseline
Score+Time+Stage+BMI+Age.
Model (a) was used to investigate changes in the mean
domain scores over time. Any signiﬁcant effects of time
in the model were investigated further using contrasts to
compare baseline mean score with mean domain score at
each follow-up time point. Models (b) and (c) were used
to investigate difference in follow-up scores between early
and advanced stage cancer adjusting for baseline score.
Model (b) has an interaction term between time and stage
that allows the effect of stage to be different at each time
point. If the interaction term in model (b) was not statisti-
cally signiﬁcant then model (c) was ﬁtted. Model (c)
allows for an overall effect of stage that does not chance
with time. An AR(1) correlation structure was used in all
models to allow for correlation between successive mea-
surements and all models were adjusted for the effect of
age and BMI.
Fitting multiple models to the subscales of questionnaires
leads to a problem of multiple testing, therefore unadjusted
p-values and conﬁdence intervals have been reported [34].
However, caution has been applied when interpreting
results, and the size of any statistically signiﬁcant changes
has been compared to a minimally important clinical differ-
ence of ten units.
Qualitative and mixed-methods analysis
All women consenting to the main questionnaire study
were contacted one month before their ﬁrst 3 month
follow-up visit and asked if they would like to participate
in an interview. If consent was obtained, an interview time
was set up and written consent obtained.
Of the 23 participants recruited for the main study, 15
women consented to an additional interview (65%). How-
ever, 11 of these women were eventually interviewed
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because one woman died and the interviewer had left the
post before completion of the three remaining interviews.
Therefore, for pragmatic reasons, we were unable to ensure
that data saturation was reached before completion of the
interviews.
To maximise diversity, women were purposively inter
viewed at different follow-up time points including
3 months (n=4: stages 1B, 1B, 1B, 4A), 6 months (n=4:
stages 1B, 1B, 3A, 3A), 9 months (n=2: stages 2, 1B)
and 12 months (n=1: stage 1B). Interviews were con-
ducted within the University of Shefﬁeld’s academic unit
of reproductive and developmental medicine by a student
not involved in the woman’s clinical care.
The interview guide was semi-structured with open
questions (see Supplementary Appendix 1). Interviews
were tape recorded, digitalised, transcribed and coded
by JT using the QSR NVivo 9 Computer-Assisted Quali-
tative Data Analysis Software. Data was analysed using a
thematic approach outlined by Braun and Clarke [35]
utilising a systematic ﬁve-step approach: familiarisation,
generating initial codes, searching for themes, reviewing
themes, deﬁning and naming themes. GJ, HW, JH and
JT collaboratively analysed and discussed emergent themes
in order to ensure a consensus was reached. Following
analysis of both sets of data, a triangulation protocol
was followed whereby the ﬁndings of the qualitative data
were coded against the quantitative data to explore where
there was agreement (convergence), complementarity,
silence (i.e. a theme arises from one data set and not
another) or dissonance (contradiction) between the study
ﬁndings [36].
Results
Twenty-three women were approached, and all were rec
ruited at baseline. Mean age was 59.9 years (SD=15.3;
range=23.8–86.6 yrs; median age=66.1 yrs), and mean
BMI was 30.0 (SD=4.5; range=24.4–38.2; median
BMI=28.6). Sixteen of the women had early stage (Stage
1B=15, Stage 2=1), and seven women had advanced
stage of disease (Stage 3A=3, 3B=1, 3C=1, Stage
4A=1, 4B=1). All of the women were of British nation-
ality, 22 were white Caucasian and 1 woman was of
mixed race. Ten (43.5%) were married, 3(13%) cohabit-
ing, 2(8.7%) single, 5(21.7%) widowed and 3 (13%)
other. Unfortunately, one woman died before her 3 month
follow-up, and two patients withdrew from the study and
had insufﬁcient data to be included in the analysis; there-
fore 20 women are included in the tables. These two
women had also not given consent to an interview.
Eighteen women underwent triple incision vulvectomy
(including a bilateral inguinofemoral lymphadectomy).
Four women underwent radical wide local excision of
the vulva and unilateral groin node dissection. Six women
received adjuvant radiotherapy with three of these women
also receiving concomitant chemotherapy (Cisplatin). One
woman with stage 4 disease received chemo-radiotherapy
but died from her disease.
The longitudinal model for the EORTC showed a signif-
icant change over time for physical functioning (p=0.010),
social functioning (p=0.049), fatigue (p=0.011) and pain
(p=0.036) (Supplemental Appendix 2).
Post-hoc comparisons of each time point with baseline
showed a signiﬁcant change (indicating a worse HRQoL)
in all these domains from baseline to 3 months (physical
functioning=14.0, 95% CI: 22.2 to 5.8, p=0.001;
social functioning=19.2, 95% CI: 32.2 to 6.1,
p=0.005; pain=17.5, 95% CI: 5.2 to 29.8, p=0.006; and
fatigue=17.8, 95% CI: 8.3 to 27.2, p<0.001). As these
mean differences are greater than the clinically important
difference of 10 but the conﬁdence interval includes
10, this change is potentially clinically important (Supple-
mental Appendix 3). No other statistically signiﬁcant reduc-
tions were observed for pain and social functioning from
baseline to 6, 9 and 12 months. However, a signiﬁcantly
worse HRQoL in physical functioning was also observed
from baseline to 9 months (14.8, 95% CI: 26.6 to
2.9, p=0.0015), and 12 months (15.0, 95% CI: 27.5
to 2.5, p=0.019) and from baseline to 6 months only for
fatigue (13.9, 95% CI: 2.4 to 25.4, p=0.019). As these
mean differences were greater than the clinically important
difference of 10 but the conﬁdence interval includes
10, this change is also potentially clinically important
(Supplementary Appendix 3).
On the SF-36, the longitudinal model showed signiﬁ-
cant declines in physical functioning (p=0.003) (Supple-
mental Appendix 2). Post-hoc comparisons of each time
point with baseline show a signiﬁcant reduction in physi-
cal functioning from baseline to 3 months (14.4, 95%
CI: 22.6 to 6.2, p=0.001). As the mean difference is
greater than the clinically important difference of 10
but the conﬁdence interval includes 10, this change is
potentially clinically important. Changes from baseline
to 6 months (10.2, 95% CI: 21.3 to 1.0, p=0.073),
9 months (3.3, 95% CI: 16.3 to 9.6, p=0.613) and
12 months (10.3, 95% CI: 24.5 to 4.0, p=0.144) were
not statistically signiﬁcant.
Using ePAQ-PF the longitudinal model showed an over-
all signiﬁcant deterioration over time (p=0.047) for the
general sex life domain (Supplemental Appendix 4). How-
ever, post-hoc comparisons of each time point with base-
line showed no signiﬁcant difference in general sex life
from baseline to 3 months (1.8, 95% CI: 6.6 to 10.3),
6 months (3.7, 95% CI: 14.1 to 6.6, p=0.470),
9 months (9.3, 95% CI 21.6 to 32.1, p = 0.137) and
12 months (2.7, 95% CI: 11.0 to 16.3, p=0.698).
Adjusting for baseline, age and BMI we found that
women with advanced compared to early stage vulval can-
cer had worse mental health at follow-up as measured on
the SF-36 (19.3; 95% CI: 37.2 to 1.3; p=0.037).
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However, no other signiﬁcant differences were observed
(Table 1).
Qualitative and mixed-methods results
Twenty overarching themes emerged from the qualitative
analysis reﬂecting the wide impact treatment for vulval
cancer had upon the women’s HRQoL over the ﬁrst year,
including: physical functioning, ability to carry out daily
activities, pain, discomfort/tenderness, lymphoedema,
fatigue, social functioning, conﬁdence, impact on work,
sexual functioning, emotional well-being, patient educa-
tion, patient information, self-identity and femininity,
body image, coping strategies, experiences of in-hospital
care, relationships with their partner, family and children.
Questionnaire scores revealed signiﬁcantly worse phys-
ical, social and sexual function, fatigue, pain and mental
health at follow-up. The results of the triangulation process
with these domains are reported in Supplemental Appen-
dix 5. The qualitative data conﬁrmed that all these areas
of HRQoL were affected as a result of vulval cancer treat-
ment suggesting a good level of agreement between the
datasets. However, a large number of sub-themes that
emerged from the qualitative analysis provided deeper
insight and complementary data as to why these question-
naire domains were negatively affected.
Physical functioning (in particular the ability to carry out
daily activities and walking) appeared most affected by
lymphoedema (particularly leg swelling) and urinary
incontinence. Mobility was also affected by the use of
drains and numbness/loss of sensation post-surgery, partic-
ularly in relation to going to the toilet. For some women
this resulted in the need for help with physical movements
and/or inactivity. Pain had a big impact on all women; in
most instances this resulted from the site of surgery and
subsequent infection and stitches. Overall, pain was
described as excruciating (although discomfort/tenderness
was also mentioned) with many women relying on pain-
killers up to at least 6 months post-treatment. However,
for some women pain was also the consequence of
lymphoedema and radiotherapy (where administered) with
women describing their skin as burnt or blistered, similar
to sunburn. Pain impacted upon many areas of physical
and sexual functioning and emotional wellbeing.
Most women described feeling very tired and lethargic.
This limited their ability to carry out simple physical tasks
(e.g. walking, standing), domestic chores at home and
work activities. Women often reduced their hours/days
and/or adapted their work routine to accommodate the
extra fatigue. Some women did report improvements in
their energy levels, 6 months post-treatment.
In relation to social functioning, relationships with fam-
ily and children and leisure activities were affected. Many
women stopped their leisure activities for a short period of
time or avoided certain social situations. This appeared to
affect their conﬁdence; incontinence and the need to be
near toilets were important issues for many women. Sexual
functioning was particularly affected; feeling worried and
frightened, a loss of interest/avoidance and lack of enjoy-
ment in sex post-treatment were often reported. Overall,
the women reported feeling nervous and anxious about
numerous other areas of their life associated with their
treatment including washing their vulva, viewing and
Table 1. Estimated regression coefﬁcients from mixed effects
repeated measures models to show the effect of cancer stage on
outcome
Time × cancer stage
interaction P-value
Cancer stage
Model
coefﬁcienta 95% CI P-value
EORTC dimension
HRQoL/global health 0.823 13.4 (30.9, 4.0) 0.124
Physical function 0.761 5.2 (18.4, 8.0) 0.420
Role function 0.598 1.1 (22.6, 20.3) 0.912
Emotional function 0.764 10.5 (34.3, 13.2) 0.362
Cognitive function 0.790 0.9 (15.9, 17.7) 0.912
Social function 0.729 4.4 (16.2, 25.0) 0.661
Fatigue 0.472 5.0 (10.8, 20.9) 0.513
Nausea 0.878 4.6 (13.3, 4.1) 0.283
Pain 0.663 14.2 (38.8, 10.4) 0.240
Dyspnoea 0.222 2.1 (18.8, 14.5) 0.791
Insomnia 0.406 7.8 (14.0, 29.6) 0.462
Appetite loss 0.847 11.7 (11.9, 35.4) 0.320
Constipation 0.891 6.9 (4.9, 18.6) 0.242
Diarrhoea 0.916 0.8 (9.4, 11.0) 0.873
Financial 0.216 7.7 (5.2, 20.5) 0.224
SF36 dimension
Physical functioning 0.559 2.2 (17.7, 13.2) 0.765
Role physical 0.248 3.6 (31.9, 39.2) 0.832
Bodily pain 0.227 4.6 (25.0, 15.9) 0.644
General health 0.083 4.1 (8.8, 16.9) 0.518
Vitality 0.482 0.8 (19.3, 17.7) 0.930
Social functioning 0.821 12.4 (34.4, 9.7) 0.253
Role emotional 0.659 15.7 (44.7, 13.3) 0.266
Mental health 0.053 19.3 (37.2, 1.3) 0.037
EPAQ dimension
Urinary pain 0.930 5.9 (1.9. 13.8) 0.127
Voiding 0.919 4.5 (10.7, 1.6) 0.139
Overactive bladder 0.473 4.4 (8.5, 17.4) 0.974
Stress incontinence 0.603 0.2 (9.4, 9.0) 0.962
Urinary HRQoL 0.996 2.9 (9.9, 15.7) 0.632
Irritable bowel 0.999 1.0 (9.0, 6.9) 0.785
Constipation 0.714 3.2 (17.5, 11.1) 0.643
Evacuation 0.329 3.2 (8.4, 2.1) 0.221
Bowel continence 0.196 2.2 (4.3, 8.7) 0.491
Bowel HRQoL 0.625 1.1 (10.1, 7.8) 0.789
Vaginal pain
and sensation
0.927 6.6 (22.0, 8.9) 0.379
Vaginal capacity 0.283 5.9 (33.5, 21.8) 0.654
Prolapse 0.951 0.9 (4.3, 2.4) 0.524
Vaginal HRQoL 0.543 5.0 (16.4, 6.4) 0.356
Sexual urinary 0.490 2.6 (16.0, 10.8) 0.660
Sexual vaginal 0.482 14.2 (35.2, 6.8) 0.154
Dyspareunia 0.265 0.5 (41.3 40.3) 0.962
General sex life 0.208 1.5 (16.0, 13.1) 0.825
aCoefﬁcient for stage from repeatedmeasuresmodel, positive value indicates higher score.
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touching their vulva, fear of cancer recurrence and their
own mortality. As a consequence, a range of emotions
were often described including feeling withdrawn and
depressed, mood swings and frustration. However, despite
experiencing such severe side effects there was signiﬁcant
evidence of resilience and positivity in the data which
helped patient’s cope with their situation.
All these themes appeared present across the dataset.
However, improved energy levels/reduced tiredness and
fear of cancer recurrence were more salient in women six
months post-treatment. The side effects of radiotherapy
were reported in women with more advanced stage disease.
Discussion
We aimed to use mixed methods to comprehensively
understand the impact that vulval cancer surgery has upon
patient outcomes and explore how this may change from
diagnosis and over the ﬁrst year post-treatment. To our
knowledge, this is the ﬁrst mixed-methods paper in this
area. Most of our patient sample underwent major surgery,
the most common procedure being a triple incision
vulvectomy (including a bilateral inguinofemoral lympha
dectomy).
Our analysis revealed that following surgery, women
experience signiﬁcant side effects; pain and fatigue in par-
ticular are typically unresolved at 12 months post-
treatment and worse than at pre-treatment. There were also
key areas of HRQoL that signiﬁcantly deteriorated over
time (physical, social and sexual functioning) that were
also unresolved at 12 months.
Overall, good convergence was observed following the
triangulation process between the quantitative and qualita-
tive data. No silent or dissonant themes emerged which sug-
gested that the questionnaires measure the relevant areas of
HRQoL. However, they lack depth as the qualitative analy-
sis revealed many complementary themes which provided a
deeper understanding for the quantitative results.
The signiﬁcant negative impact upon physical function-
ing was identiﬁed by both the EORTC QLQ-C30 and the
SF-36. Our ﬁndings are similar to a previous study [25]
whereby, in women who underwent inguinofemoral lymph-
adenectomy, worse physical and role functioning were
reported at 6 months after surgery compared to baseline.
Symptoms most attributed to the problems in ‘physical
functioning’ appeared to be pain and lymphoedema.
Lymphoedema is a well reported side effect of surgery for
vulval cancer following groin dissection [37]. de Melo and
colleagues [21] also observed a signiﬁcant correlation
between lymphoedema of the lower extremities (LLE) and
worse physical functioning. Whilst Sentinel node biopsy
may result in less treatment-related lymphoedema [22,24],
unfortunately it is not available to patients at our institution.
As well as describing how lymphoedema impacted
upon mobility, women also described it as causing numb
ness, pain and tiredness. These side effects impacted upon
psychological and social functioning which is supported
by other studies [37,38]. On the EORTC, we found pain
and fatigue got signiﬁcantly worse over time. Novackova
et al. [30] also observed more fatigue 6 months after sur-
gery compared to baseline. Although, it is most likely that
lymphoedema was a main contributor to these outcomes,
from the qualitative analysis, women described other side
effects such as wound infections, drains and also skin
blistering/burning from the radiotherapy that caused pain
and contributed to these negative HRQoL outcomes.
Overall, the women perceived these side effects as severe
and enduring, affecting social functioning, their conﬁ-
dence and emotional health which is similar to other qual-
itative literature in this area [11,15]. Mental health was
observed to be signiﬁcantly worse in women with
advanced compared to early stage disease. This is perhaps
not surprising given the prognosis that women with
advanced stage vulval cancer face and additional psycho-
logical support may be of beneﬁt for this group of women.
The negative impact that vulval cancer surgery has
upon the sexual functioning of women has been well
described [10,16]. We found a signiﬁcant difference on
the general sex life domain of the e-PAQ-PF which sug-
gests that there was a negative change over time. A high
number of our sample had also undergone a lymphadenec-
tomy which has also been reported elsewhere as having a
signiﬁcant negative impact on sexual function [24]. A
recent study reported no signiﬁcant differences in psycho-
social and sexual functioning for women with vulvar can-
cer before and after vulvectomy 12 months post-treatment.
However, a different set of questionnaires were used in
that study which may explain the ﬁndings [27].
On the ePAQ-PF, domains can be skipped if it is not rel-
evant to the patient. A high proportion of the women had
skipped the sex domain questions. One reason for this
may be because they did not have a partner as suggested
by the demographic data (only 13/23 women reported hav-
ing a partner). Alternatively, women may not have
resumed their sex life (regardless of their relationship
status) because of the impact of the surgery. Indeed, the
latter was supported from the qualitative analysis which
revealed that pain from surgery had prevented most
women from engaging in penetrative sex at least up to
six months post-treatment and made the use of dilators
difﬁcult and challenging.
There are a few limitations to the study. Whilst we
achieved very low loss to follow-up rates, as with most
vulval cancer studies, it is a small study and so may not
have established if women with more advanced stage
disease do have greater physical morbidity. It is also a sin-
gle institution study and so might be biassed as a result.
However, it is a non-selected group of women going
through treatment and therefore may reﬂect the average
outcome of care compared with a clinical trial. Despite a
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particularly young patient in the study, the median age and
BMI of the patients are also consistent with the sample of
women who usually present with vulval cancer. There
were many themes that resonated with all women in the
study. However, because just over half of the sample were
interviewed, it is possible that the views presented do not
extend to other women in the sample (on which the quan-
titative ﬁndings are based). Also, because of the aforemen-
tioned pragmatic reasons data saturation cannot be
assumed which is another potential limitation to the pres-
ent ﬁndings.
Conclusion
We found that women who undergo treatment for vulval
cancer report high rates of treatment-related morbidity.
The impact of surgery appeared to most negatively affect
physical and social functioning and increase fatigue and
pain post-treatment. Recovery from treatment can be a
slow process and surgery has long-term implications.
Issues relating to morbidity are widely ignored during
the treatment phase and most patient information re-
sources are not explicit in conveying these risks. This
study will allow more accurate information to be provided
to future patients. Better management of treatment side ef-
fects (particularly pain and fatigue) may lead to impro
vements in HRQoL which need to be monitored and man-
aged closely throughout at least the ﬁrst year from diagno-
sis. The high rates of morbidity relating to lymphoedema
and sexual function re-enforce the need for specialist
clinics to support women who suffer these complications.
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